Aromatase expression and regulation in breast and endometrial cancer
Authors:
- 1 July 2016
- journal article
- review article
- Published by Bioscientifica in Journal of Molecular Endocrinology
- Vol. 57 (1) , R19-R33
Abstract
Long-term exposure to excess estrogen increases the risk of breast cancer and type 1 endometrial cancer. Most of the estrogen in premenopausal women is synthesized by the ovaries, while extraovarian subcutaneous adipose tissue is the predominant tissue source of estrogen after menopause. Estrogen and its metabolites can cause hyperproliferation and neoplastic transformation of breast and endometrial cells via increased proliferation and DNA damage. Several genetically modified mouse models have been generated to help understand the physiological and pathophysiological roles of aromatase and estrogen in the normal breast and in the development of breast cancers. Aromatase, the key enzyme for estrogen production, is comprised of at least ten partially tissue-selective and alternatively used promoters. These promoters are regulated by distinct signaling pathways to control aromatase expression and estrogen formation via recruitment of various transcription factors to their cis-regulatory elements. A shift in aromatase promoter use from I.4 to I.3/II is responsible for the excess estrogen production seen in fibroblasts surrounding malignant epithelial cells in breast cancers. Targeting these distinct pathways and/or transcription factors to modify aromatase activity may lead to the development of novel therapeutic remedies that inhibit estrogen production in a tissue-specific manner. Abstract Long-term exposure to excess estrogen increases the risk of breast cancer and type 1 endometrial cancer. Most of the estrogen in premenopausal women is synthesized by the ovaries, while extraovarian subcutaneous adipose tissue is the predominant tissue source of estrogen after menopause. Estrogen and its metabolites can cause hyperproliferation and neoplastic transformation of breast and endometrial cells via increased proliferation and DNA damage. Several genetically modified mouse models have been generated to help understand the physiological and pathophysiological roles of aromatase and estrogen in the normal breast and in the development of breast cancers. Aromatase, the key enzyme for estrogen production, is comprised of at least ten partially tissue-selective and alternatively used promoters. These promoters are regulated by distinct signaling pathways to control aromatase expression and estrogen formation via recruitment of various transcription factors to their cis-regulatory elements. A shift in aromatase promoter use from I.4 to I.3/II is responsible for the excess estrogen production seen in fibroblasts surrounding malignant epithelial cells in breast cancers. Targeting these distinct pathways and/or transcription factors to modify aromatase activity may lead to the development of novel therapeutic remedies that inhibit estrogen production in a tissue-specific manner.Keywords
This publication has 129 references indexed in Scilit:
- Estrogen synthesis and signaling pathways during aging: from periphery to brainTrends in Molecular Medicine, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Weight gain increases human aromatase expression in mammary glandMolecular and Cellular Endocrinology, 2012
- Aromatase, breast cancer and obesity: a complex interactionTrends in Endocrinology & Metabolism, 2012
- Comparison of Increased Aromatase versus ERα in the Generation of Mammary Hyperplasia and CancerCancer Research, 2011
- Body Fat Distribution and Risk of Premenopausal Breast Cancer in the Nurses' Health Study IIJNCI: Journal of the National Cancer Institute, 2010
- Adult Body Size, Hormone Receptor Status, and Premenopausal Breast Cancer Risk in a Multiethnic Population: The San Francisco Bay Area Breast Cancer StudyAmerican Journal of Epidemiology, 2010
- Regulation of breast cancer-associated aromatase promotersCancer Letters, 2009
- Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal WomenJNCI: Journal of the National Cancer Institute, 2008
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002